SAREPTA THERAPEUTICS, INC. (NASDAQ:SRPT) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On July19, 2017, Sarepta Therapeutics, Inc. issued a press release announcing its results of operations and financial condition for the three months ended June30, 2017. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The information in this report furnished to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished to Item 2.02 of this report.
| Item 2.02 | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit Number |
Description |
| 99.1 | Press release, dated July19, 2017. |
Sarepta Therapeutics, Inc. ExhibitEX-99.1 2 d416558dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments — Achieved net revenue of $35 million for the second quarter 2017 — — Increased revenue guidance range to $125 – $130 million for the year — — Entered into global settlement and license agreements resolving exon skipping patent disputes with BioMarin — — Entered into a micro-dystrophin gene therapy research collaboration with Genethon — CAMBRIDGE,…To view the full exhibit click here
About SAREPTA THERAPEUTICS, INC. (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
